# A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

> **NCT05757102** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 292 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FF/UMEC/VI
- **DEVICE:** ELLIPTA
- **DRUG:** FF/VI

## Key facts

- **NCT ID:** NCT05757102
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-25
- **Primary completion:** 2027-01-15
- **Final completion:** 2027-01-15
- **Target enrollment:** 292 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05757102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05757102, "A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05757102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*